Clinical Trials Sponsored by Myeloma UK

Total 1037 results

University of Leeds
Celgene; Myeloma UK

Active, not recruiting

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUKseven)

Multiple Myeloma

United Kingdom
University of Leeds
Karyopharm Therapeutics Inc; Myeloma UK

Withdrawn

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma (MUKfourteen)

Myeloma Multiple

United Kingdom
University of Leeds
Celgene; Janssen, LP; Myeloma UK

Active, not recruiting

MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)

Multiple Myeloma

United Kingdom
University of Leeds
Millennium Pharmaceuticals, Inc.; Myeloma UK

Unknown

Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (MUKEight)

Multiple Myeloma

United Kingdom
University of Leeds
Celgene Corporation; Oncolytics Biotech; Myeloma UK

Unknown

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)

Multiple Myeloma

United Kingdom
University of Leeds
Merck Sharp & Dohme LLC; Myeloma UK

Completed

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) (MUKfour)

Multiple Myeloma

United Kingdom
Prof Jamie Cavenagh
Novartis; Myeloma UK

Unknown

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma (MUKsix)

Multiple Myeloma

United Kingdom
European Myeloma Network

Completed

A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe

AL Amyloidosis

Netherlands, Czechia, Austria, France, Germany, Greece, Italy, Portugal, Spain, United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
European Myeloma Network

Completed

Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (EMN-alloRIC)

Multiple Myeloma | Hematologic Malignancies

Spain, Sweden, Germany, Italy
European Myeloma Network

Completed

A Trial for Systemic Light-chain (AL) Amyloidosis (EMN-03)

AL Amyloidosis

Italy
Multiple Myeloma Research Foundation

Active, not recruiting

MMRF Molecular Profiling Protocol

Multiple Myeloma | Plasma Malignancy

United States, Canada
Canadian Myeloma Research Group

Completed

A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse

Canada
Nordic Myeloma Study Group

Completed

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Multiple Myeloma

Denmark, Sweden, Norway
European Myeloma Network
Pfizer

Not yet recruiting

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

Smoldering Multiple Myeloma

Netherlands, Finland, Norway, France, Italy, Greece
Multiple Myeloma Research Foundation

Terminated

MMRF CureCloud Research Initiative

Multiple Myeloma

United States
Canadian Myeloma Research Group

Active, not recruiting

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

Multiple Myeloma

Canada
Canadian Myeloma Research Group

Completed

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP)

Multiple Myeloma

Canada
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
Canadian Myeloma Research Group

Not yet recruiting

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients (BOREALIS)

Multiple Myeloma
European Myeloma Network
GlaxoSmithKline

Recruiting

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)

AL Amyloidosis

Germany, Netherlands, France, Greece, Italy, United Kingdom
Nordic Myeloma Study Group

Unknown

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Multiple Myeloma

Denmark
Canadian Myeloma Research Group
GlaxoSmithKline

Recruiting

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

Relapsed and/or Refractory Multiple Myeloma

Canada
European Myeloma Network
Janssen, LP

Active, not recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)

Multiple Myeloma | Extramedullary Plasmacytoma

Turkey, Italy, Greece
Amgen
Multiple Myeloma Research Foundation

Approved for marketing

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Multiple Myeloma
European Myeloma Network
Janssen Pharmaceutica

Active, not recruiting

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Light Chain (AL) Amyloidosis, Stage 3B

Netherlands, Greece, France, Italy
European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Celgene
Multiple Myeloma Research Consortium

Completed

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Stichting European Myeloma Network
Janssen, LP

Recruiting

European Myeloma Network (EMN) Sample Project (EMN36)

Multiple Myeloma | Smoldering Multiple Myeloma | Plasma Cell Leukemia | MGUS | Extramedullary Myeloma

Italy, Austria, Czechia, Greece, Serbia
Cancer Research UK
Vaccitech (UK) Limited

Recruiting

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Aarogyam UK

Completed

Ayurveda for Flu Like Illness During Covid-19 Outbreak

Flu Like Illness

United Kingdom
Aarogyam UK

Completed

Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak

Flu Like Symptom | Flu Like Illness

United Kingdom
Intergroupe Francophone du Myelome

Recruiting

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma (RHUMM)

Multiple Myeloma

France
Intergroupe Francophone du Myelome

Terminated

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma (Covimmunomm)

Covid19 | Multiple Myeloma

France
Intergroupe Francophone du Myelome

Completed

Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone

Myeloma

France
Intergroupe Francophone du Myelome

Completed

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies (MOZOBIL)

Multiple Myeloma | Blood Stem Cell Transplant Failure

France
Aarogyam UK

Unknown

Integrative Yoga Therapy for Patients With Chronic Pain and Psychological Distress

Chronic Pain | Psychological Distress

United Kingdom
Aarogyam UK

Completed

Tele-Yoga Therapy for Chronic Pain

Chronic Pain

United Kingdom
Aarogyam UK

Unknown

Evaluating Chronic Pain Management Program

Chronic Musculoskeletal Pain
Intergroupe Francophone du Myelome

Unknown

Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

Multiple Myeloma

France, Belgium
Myeloid Therapeutics

Suspended

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Lymphoma, T-Cell, Peripheral | Cell Therapy | Adoptive Cellular Immunotherapy

United States
Aarogyam UK
Patanjali Yog Peeth (UK) Trust

Completed

Efficacy of Yoga Based Self-Management Program for Chronic Pain

Chronic Pain

United Kingdom
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
European Myeloma Network
Karyopharm Therapeutics Inc

Recruiting

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Multiple Myeloma

Spain, United States, Germany, Netherlands, Greece, France, Italy
Mayo Clinic
Multiple Myeloma Research Foundation

Completed

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | t(11;14)

United States
European Myeloma Network
EMN Research Italy

Active, not recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Multiple Myeloma

Czechia, Greece, Italy
European Myeloma Network
Fondazione EMN Italy Onlus

Completed

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Multiple Myeloma

Italy
European Myeloma Network
University of Turin, Italy

Completed

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (CPD)

Multiple Myeloma

Italy
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
Odense University Hospital
Danish Myeloma Study Group

Active, not recruiting

Quality of Life the Danish Multiple Myeloma Patients (QoL-MM)

Quality of Life | Multiple Myeloma

Denmark

Clinical Trials Sponsored by Myeloma UK

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations